Schwalbach/Taunus, Germany

Erhard Rossmanith


Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 1989-1999

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Erhard Rossmanith: Innovator in Nerve Damage Treatment

Introduction

Erhard Rossmanith is a notable inventor based in Schwalbach/Taunus, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the treatment of nerve damage. With a total of 2 patents, his work focuses on innovative solutions for medical challenges.

Latest Patents

Rossmanith's latest patents include the use of xanthine derivatives for the treatment of nerve damage following an interruption in blood circulation. This invention relates to the use of specific xanthine derivatives that can be formulated into medicaments aimed at preventing and treating nerve damage. The compounds he has developed are designed to address inflammatory and painful disorders, particularly those associated with rheumatic conditions.

Career Highlights

Throughout his career, Rossmanith has been associated with Hoechst Aktiengesellschaft, a prominent company in the pharmaceutical industry. His work has led to the development of novel xanthine derivatives, which are prepared through specific chemical processes involving homopiperazine and its derivatives. These innovations have the potential to significantly impact the treatment of nerve-related ailments.

Collaborations

Rossmanith has collaborated with esteemed colleagues such as Erhard Wolf and Robert R Bartlett. Their combined expertise has contributed to the advancement of research in the field of medicinal chemistry.

Conclusion

Erhard Rossmanith's contributions to the treatment of nerve damage through innovative xanthine derivatives highlight his role as a key inventor in the pharmaceutical industry. His work continues to pave the way for new therapeutic options in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…